North America Pharmaceutical Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Route of Administration ; Application ; End User ; and Country

June 2020 •
145 pages •
Report ID: 5915451 •
Format: PDF

Summary
Table of contents
Search Inside

The North America pharmaceutical drug delivery market is anticipated to reach US$ 9,36,148.9 Mn by 2027 from US$ 5,60,491.5 Mn in 2019; the market is projected to grow at a CAGR of 6.8% from 2019 to 2027.

The growth of the North America pharmaceutical drug delivery market is primarily attributed to the increasing prevalence of chronic diseases.However, the high cost of drug delivery device development is among the major factor limiting the growth of the market.

Further, growth in drug delivery technology and innovations is expected to have a positive impact on the growth of the North American pharmaceutical drug delivery market in the coming years.

Drug delivery systems are medical devices used to inject drugs or therapeutic chemicals into the body.Several types of the drug delivery systems available in the market include transmucosal, oral, pulmonary, injectable, topical, nasal, implantable, and ocular, among others.

These systems are enabled with the technologies that are primarily used to have a controlled or targeted delivery of various therapeutic agents for the treatment of multiple diseases.

Many healthcare stakeholders in North American countries are focusing on changing the overall landscape of the oral, topical, transmucosal, subcutaneous, and other markets to deliver better health care.The increasing rate of chronic diseases such as cardiovascular disease (CVD) and diabetes is one of the main factors contributing to the upsurge in pharmaceutical drug delivery industry in North America.

Due to the hectic present-day lifestyle, CVDs such as angina pectoris, therosclerosis, and acute myocardial infarction have been acting as a significant cause of mortality, not only in North America but also in the whole world.In Canada, CVDs are the second leading cause of deaths.

According to Health Canada, ~1 in 12 Canadians, aged 20 and above, live with a diagnosed heart disease in the country. Moreover, according to the World Heart Federation (WHF), noncommunicable diseases, including cardiovascular diseases, accounted for ~77% of total deaths in Mexico in 2016.

Diabetes is one of the life-threatening chronic diseases with no functional cure, and it can increase the overall risk of premature death.Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes.

As there is a significant increase in diabetes cases worldwide, it is resulting in life-changing complications among the population.According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which has been expected to reach 62 million by 2045.

The disease prevalence is likely to rise by ~35% during the forecast period. Exogenous insulin is usually administered through a subcutaneous route. owing to the above mentioned factors propelling the growth of the pharmaceutical drug delivery market in North America.

In 2019, injectable drug delivery accounted for the largest share in the North American pharmaceutical drug delivery market, based on the route of administration. However, the topical drug delivery segment is estimated to mark the highest CAGR in the market during the forecast period owing to the increasing number of patients with skin diseases and gradual shift in patient preference for novel transdermal delivery systems.
Several significant primary and secondary sources related to this study on the pharmaceutical drug delivery market in North America are Centers For Disease Control And Prevention (CDC), Food and Drug Administration (FDA), Ministry of Health and Prevention (MoHAP), Ministry of Health and Family Welfare (MoHFW), and American Cancer Society (ACS), among others.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager